|Mr. Carlo Rosa||CEO, GM & Exec. Director||N/A||N/A||51|
|Dr. Chen Menachem Even||Chief Commercial Officer and Exec. Director||N/A||N/A||54|
|Mr. Piergiorgio Pedron||Chief Financial Officer and Sr. Corp. VP||N/A||N/A||46|
|Riccardo Fava||Sr. Director of Investor Relations & Corp. Communication||N/A||N/A||N/A|
|Mr. Marco Minolfo||Director of Corp. Legal Affairs Department and Standing Sec.||N/A||N/A||N/A|
DiaSorin S.p.A. engages in the development, production, and commercialization of diagnostic tests that are designed for hospital and private testing laboratories for use in various clinical areas in the market of immunodiagnostics and molecular diagnostics. The company offers immunodiagnostics products in the areas of infectious diseases; bone and mineral metabolism; endocrinology, including diabetes, thyroid function, fertility, growth, adrenal function, and gastroenterology; hypertension; oncology; gastrointestinal infections; autoimmunity; and cardiac and brain damages. Its immunodiagnostics systems include LIAISON XL, an automated chemiluminescence analyzer; LIAISON analyzer; ETI Max 3000, an automated microtiter plate analyzer; EVOlyzer 2-150/8 with disposable tips; and ELISA washers and readers. The company also offers molecular diagnostic products for oncology, hematology, and infectious diseases; systems, including LIAISON IXT and BULLET Pro to extract the nucleic acid from various biological samples; and LIAISON IAM to diagnose and monitor various infectious diseases and onco-hematology parameters. It sells its products directly, as well as through an international network of independent distributors in Europe, Africa, Central America, South America, the Asia Pacific, and North America. DiaSorin S.p.A. was founded in 1968 and is headquartered in Saluggia, Italy.
DiaSorin S.p.A.’s ISS Governance QualityScore as of August 1, 2017 is 7. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 6; Compensation: 8.